Skip to main content

Table 2 In-vitro kinase inhibitory activities of 7, 1315, and sunitinib

From: Structural optimization and evaluation of novel 2-pyrrolidone-fused (2-oxoindolin-3-ylidene)methylpyrrole derivatives as potential VEGFR-2/PDGFRβ inhibitors

Compound R IC50 (nM) % inhibition of Aurora A at 1.0 μM
VEGFR-2 PDGFRβ
Sunitinib 151.8 94.5 50.7
7 –SO2N(CH2CH2Cl)2 23.7 63.2 94.4
13 –OMe 47.8 76.2 92.9
14 –OH 25.9 28.5 93.6
15 –SH 14.6 12.1 96.4
\